The American Gastroenterological Association released guidelines for hepatocellular carcinoma treatment Feb. 22.
Four recommendations from the AGA:
1. Systemic therapies are only recommended for those in stage C with preserved liver function. Atezolizumab and bevacizumab are recommended for first-line treatments rather than sorafenib.
2. Those in stage 0 and A who are also eligible for ablation, resection or transplant should receive curative surgery rather than systemic therapies.
3. Transarterial chemoembolization should be the first-line treatment for those in stage B.
4. Stage D patients should not receive systemic therapies. Instead, they should receive a transplant or best supportive care.
